Interrupting prolonged sitting with frequent short bouts of light‐intensity activity in people with type 1 diabetes improves glycaemic control without increasing hypoglycaemia: The SIT‐LESS randomised controlled trial
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15254 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Matthew D Campbell und 7 weiteren Autor:innen. Beteiligte Einrichtung: John Dawson Drug Discovery and Development Institute, University of Sunderland, Sunderland, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Hypoglycemia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Diabetes UK.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To examine the impact of interrupting prolonged sitting with frequent short bouts of light‐intensity activity on glycaemic control in people with type 1 diabetes (T1D). Materials and Methods In total, 32 inactive adults with T1D [aged 27.9 ± 4.7 years, 15 men, diabetes duration 16.0 ± 6.9 years and glycated haemoglobin 8.4 ± 1.4% (68 ± 2.3 mmol/mol)] underwent two 7‐h experimental conditions in a randomised crossover fashion with >7‐day washout consisting of: uninterrupted sitting (SIT), or, interrupted sitting with 3‐min bouts of self‐paced walking at 30‐min intervals (SIT‐LESS). Standardised mixed‐macronutrient meals were administered 3.5 h apart during each condition. Blinded continuous glucose monitoring captured interstitial glucose responses during the 7‐h experimental period and for a further 48‐h under free‐living conditions.
Results
SIT‐LESS reduced total mean glucose (SIT 8.2 ± 2.6 vs. SIT‐LESS 6.9 ± 1.7 mmol/L, p = .001) and increased time in range (3.9‐10.0 mmol/L) by 13.7% (SIT 71.5 ± 9.5 vs. SIT‐LESS 85.1 ± 7.1%, p = .002). Hyperglycaemia (>10.0 mmol/L) was reduced by 15.0% under SIT‐LESS (SIT 24.2 ± 10.8 vs. SIT‐LESS 9.2 ± 6.4%, p = .002), whereas hypoglycaemia exposure (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- John Dawson Drug Discovery and Development Institute, University of Sunderland, Sunderland, UK.
- Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine, University of Leeds, Leeds, UK.
- Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
- School of Food Science and Nutrition, Faculty of Environment, University of Leeds, Leeds, UK.
- Ministry of Health, Farwaniya Hospital, Kuwait, Kuwait.
- Diabetes Research Centre, University of Leicester, Leicester, UK.
ORCID-Profile: Matthew D Campbell, Sam M Pearson, Noppadol Kietsiriroje
Förderung
- Diabetes UK
Zitieren
APA
Campbell, M. D., Alobaid, A. M., Hopkins, M., Dempsey, P. C., Pearson, S. M., Kietsiriroje, N., Churm, R., & Ajjan, R. A. (2023). Interrupting prolonged sitting with frequent short bouts of light‐intensity activity in people with type 1 diabetes improves glycaemic control without increasing hypoglycaemia: The SIT‐LESS randomised controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15254
Vancouver
Campbell MD, Alobaid AM, Hopkins M, Dempsey PC, Pearson SM, Kietsiriroje N, et al. Interrupting prolonged sitting with frequent short bouts of light‐intensity activity in people with type 1 diabetes improves glycaemic control without increasing hypoglycaemia: The SIT‐LESS randomised controlled trial. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15254
BibTeX
@article{Campbell2023,
author = {Campbell, Matthew D and Alobaid, Anwar M and Hopkins, Mark and Dempsey, Paddy C and Pearson, Sam M and Kietsiriroje, Noppadol and Churm, Rachel and Ajjan, Ramzi A},
title = {Interrupting prolonged sitting with frequent short bouts of light‐intensity activity in people with type 1 diabetes improves glycaemic control without increasing hypoglycaemia: The SIT‐LESS randomised controlled trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15254}
}
EUVIMED